Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

Petros Grivas, MD, PhD, physician of the Seattle Cancer Care Alliance; associate professor in the Department of Medicine in the Division of Oncology and clinical director of the Genitourinary Cancers Program at the University of Washington School of Medicine; and associate member of the Clinical Research Division at Fred Hutchinson Cancer Center, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

​The phase 3 JAVELIN Bladder 100 trial ​randomized patients with unresectable locally advanced or metastatic urothelial carcinoma to frontline avelumab (Bavencio) maintenance plus best supportive care (BSC) versus BSC alone.

Avelumab plus BSC demonstrated statistically significant overall survival and progression-free survival benefits compared with BSC alone across all prespecified subgroups, ​Grivas says.

Moreover, the benefits were observed regardless of patients’ best response to induction chemotherapy and ​site of metastasis at baseline.

As such, all patients with ​advanced urothelial carcinoma who derive a response or stable disease ​from induction chemotherapy should receive avelumab maintenance, Grivas concludes.